case_images: PMC6899289_01
case_images: Baseline chest CT showing a large mass originating from the right thyroid lobe (a), with lung metastases (b), and hilar and mediastinal lymph nodes (c). (a), (c) images in mediastinal window. (b) image in lung window.
case_images: CRIE2019-9095753.001.jpg
case_images: PMC6899289_01_CRIE2019-9095753.001.jpg
case_images: fig1
case_images: There were multiple pathologically enlarged cervical, supraclavicular and mediastinal lymph nodes as well as multiple bilateral lung metastases (Figure 1).
case_images: Chest CT after 3 cycles of pembrolizumab showing marked regression of primary tumor (a), lung metastases and (b), lymph nodes (c).
case_images: CRIE2019-9095753.002.jpg
case_images: PMC6899289_01_CRIE2019-9095753.002.jpg
case_images: fig2
case_images: After only 2 cycles, the patient noticed a marked improvement of dysphagia and after 3 cycles, a near complete response was seen on CT (Figure 2).
case_images: Chest CT 6 months after start of pembrolizumab showing ongoing response.
case_images: CRIE2019-9095753.003.jpg
case_images: PMC6899289_01_CRIE2019-9095753.003.jpg
case_images: fig3
case_images: There were no signs of extra-cranial tumor progression (Figure 3).